Connect with us

Published

on

Senate Republicans, who are battling to win back the majority in 2024, worry the controversy surrounding Rep. George Santos (R-N.Y.) has become a liability for their party as a whole, and several are expressing quiet support for Sen. Mitt Romney’s (R-Utah) call for Santos to step down. 

GOP senators are reluctant to tell their House Republican counterparts what to do, but they privately hope Speaker Kevin McCarthy (R-Calif.) won’t let the situation fester for much longer.

Senate Republicans feel like they have a good chance of winning back control of the upper chamber and don’t want Santos — or other high-profile conservative House members who made a splash at President Biden’s State of the Union address — to become emblematic of their party, which could turn off independent and swing voters. 

Romney’s frustration with Santos was on display to the nation on Tuesday when he confronted the freshman lawmaker as he walked down the House center aisle, bluntly telling his fellow Republican: “You don’t belong here.”  

After the address, Romney told reporters Santos’s presence at Biden’s speech was an “embarrassment” and said he was disappointed that McCarthy hasn’t called on him to resign.  

Other Senate Republicans aren’t willing to be so bold and outspoken, but they generally agree that Santos is a distraction and should have the good sense to step down from Congress, which would spare them the spectacle of having to watch McCarthy dodge questions about the freshman’s future.  

“I am surprised that the man has not resigned, and I think it just speaks to his own lack of self-awareness and what he has done to [the] institution,” Sen. Lisa Murkowski (R-Alaska) said of Santos. 

“It’s not like we’ve got a really strong public approval rating. It doesn’t do much to elevate us in the eyes of the American public when it would appear we are kind of protecting somebody just because he’s a member of our caucus,” she said. 

“And so I’m surprised he hasn’t resigned and there hasn’t been a greater push or call for him to step out by his constituents,” she added. 

Murkowski and other GOP senators are marveling over how Santos even won in a competitive House district that was previously represented by a Democrat.  

“How does an individual who would fabricate aspects of his life story in order to gain election successfully gain election?” Murkowski asked.

She said the fact that few people bothered to examine Santos’s background closely before the election was a troubling statement about how partisanship has come to dominate today’s politics. 

“It is a telling statement about us too, that all we want is your label. All we want is your label. All we want is your label. We don’t care about your integrity, your character or whether or not you are a liar. We just want to know whether you are an R vote or a D vote,” she said.  

But while Senate Republicans worry that drama in the House may tarnish the broader party, they are loath to tell House Republicans how to run their own business.  

“I wouldn’t have done it,” said Sen. Kevin Cramer (R-N.D.) when asked about Romney’s confrontation with Santos on the House floor. “We’re always visitors in their chamber” during State of the Union addresses.  

“I don’t disagree with Mitt’s sentiment, I’ll put it that way,” Cramer said.  

Senate Republican Whip John Thune (R-S.D.) described Romney as “a principled guy who generally says what he thinks.” 

“He made a fairly strong statement there, and I think that statement stands on its own,” he said.  

A Republican senator who requested anonymity to discuss Santos said “what happens in the House certainly has a consequence to the Senate, senators or Republicans, generally.”  

But the lawmaker said senators are reluctant to publicly tell McCarthy what to do about what they acknowledge is becoming a public relations problem.  

“My policy is not to meddle in what goes on in the House. They can decide. And every time it’s an elected official or colleague, it becomes more difficult to say someone should resign because the voters made a choice,” the lawmaker explained. “In this case, they apparently made a choice based on a whole lot of wrong information.” 

The senator said it’s more important that fellow House Republicans — instead of Romney — call for Santos’s resignation.  

“I think it needs to be said by his colleagues in the House,” the source said. “There’s nothing wrong with a frank discussion about how you’re harming the brand or your behavior is not acceptable to the norms of Congress.” 

Other Senate Republicans are staying mum on the topic of Santos.  

Asked if she had any thoughts on the New York lawmaker in light of Romney’s public rebuke, Sen. Susan Collins (R-Maine) declined to comment.  

Sen. Lindsey Graham (R-S.C.) shrugged when asked about Romney’s harsh rebuke of Santos. 

“Everybody’s entitled to their opinion,” he said.  

At the same time, some Democrats are seizing on Republicans’ reluctance to condemn Santos to question the broader party’s integrity.  

Sen. Mazie Hirono (D-Hawaii) said Romney did the right thing.  

“I’m glad somebody in the Republican Party has the integrity to say to Santos who has lied every step of the way … you should not be serving,” she said.   GOP races from Medicare, Social Security third rail The Memo: Trump and Biden find common enemy in DeSantis

“It says to me that the rest of them are a pretty sad bunch of people if they’re not going to step up for the truth or integrity,” she said of Republicans who don’t want to press for Santos’s resignation.  

“It’s disappointing but not unexpected,” she added, noting that many Republicans have denied the result of the 2020 presidential election. 

“To the extent that there are all these people in that party does not reflect well on them at all,” she added.  

Continue Reading

Business

UK economy grows – ONS

Published

on

By

UK economy grows - ONS

The economy performed better than expected in February, growing by 0.5% according to official figures released on Friday, but comes ahead of an expected hit from the global trade war.

The standard measure of an economy’s value, gross domestic product (GDP), rose in part thanks to a suprisingly strong performance from the manufacturing sector, data from the Office for National Statistics (ONS) suggested.

Following the publication of the figures, the British pound rose against the dollar, jumping 0.4% against the greenback to $1.3019 within an hour.

Analysts had been forecasting just a 0.1% GDP hike in the lead-up to the announcement, according to data from LSEG.

Chancellor of the Exchequer Rachel Reeves described the results as “encouraging”, but struck a cautious tone when alluding to US President Donald Trump’s tariffs, and the economic volatility of the past week.

“The world has changed, and we have witnessed that change in recent weeks,” she said.

“I know this is an anxious time for families who are worried about the cost of living and British businesses who are worried about what this change means for them,” Ms Reeves added. “This government will remain pragmatic and cool-headed as we seek to secure the best deal with the United States that is in our national interest.”

More on Uk Economy

But back in February, when Mr Trump was just beginning his second term in office, the UK’s economy looked to be on firmer ground.

Service sectors like computer programming, telecoms and car dealerships all had strong a month, while manufacturing industries such as electronics and pharmaceuticals also helped to drive GDP growth in February.

Car manufacturing also picked up after its recent poor performance.

“The economy grew strongly in February with widespread growth across both services and manufacturing industries,” said Liz McKeown, ONS Director of Economic Statistics.

While motor vehicle manufacturing and retail both grew in February 2025, they remain below February 2024 levels by 10.1% and 1.1% respectively

This aligns with industry data showing year-on-year declines in registrations and manufacturing.

“The UK economy expanded by 0.5% in February, surprising but welcome positive news,” said Hailey Low, Associate Economist at the National Institute of Economic and Social Research.

“However, heightened global uncertainty and escalating trade tensions mean the outlook remains uncertain, with a likely reduced growth rate this year due to President Trump’s “Liberation Day” announcements.”

Ms Low said that this could create a dilemma for Ms Reeves, who would face difficult decisions later in the year when the chancellor presents her next budget.

The latest data also shows a jump from January, when the economy was flat. And compared to the same month a year ago, GDP was 1.4% higher in February 2025.

You can receive breaking news alerts on a smartphone or tablet via the Sky News app. You can also follow us on WhatsApp and subscribe to our YouTube channel to keep up with the latest news.

Continue Reading

UK

‘I don’t look at myself as a dying person anymore’: New drug that slows incurable breast cancer now available on the NHS

Published

on

By

'I don't look at myself as a dying person anymore': New drug that slows incurable breast cancer now available on the NHS

A groundbreaking new cancer treatment, hailed by patients as “game-changing”, will be available via the NHS from today.

The drug capivasertib has been shown in trials to slow the spread of the most common form of incurable breast cancer.

Taken in conjunction with an already-available hormonal therapy, it has been shown in trials to double how long treatment will keep the cancer cells from progressing.

“I don’t look at myself anymore as a dying person,” says Elen Hughes, who has been using the drug since February this year.

“I look at myself as a thriving person, who will carry on thriving for as long as I possibly can.”

Ellen Hughes has been using the drug capivasertib
Image:
Elen Hughes says capivasertib has extended her life and improved its quality

Mrs Hughes, from North Wales, was first diagnosed with primary breast cancer in 2008.

Eight years later, then aged 46 and with three young children, she was told the cancer had returned and spread.

More on Cancer

She says that capivasertib, which she has been able to access via private healthcare, has not only extended her life but improved its quality with fewer side effects than previous medications.

It also delays the need for more aggressive blanket treatments like chemotherapy.

New breast cancer drug capivasertib
Image:
Capivasertib is now available from the NHS

“What people don’t understand is that they might look at the statistics and see that [the therapy] is effective for eight months versus two months, or whatever,” says Mrs Hughes.

“But in cancer, and the land that we live in, really we can do a lot in six months.”

Mrs Hughes says her cancer therapy has allowed her “to see my daughter get married” and believes it is “absolutely brilliant” that the new drug will be available to more patients via the NHS.

The National Institute for Health and Care Excellence approved capivasertib for NHS-use after two decades of research by UK teams.

Professor Nicholas Turner, from the Institute of Cancer Research which led the study, told Sky News it was a “great success story for British science”.

Professor Nicholas Turner, from the Institute of Cancer Research which led the study
Image:
Professor Nicholas Turner wants urgent genetic testing of patients with advanced breast cancers to see if they could benefit

The new drug is suitable for patients’ tumours with mutations or alterations in the PIK3CA, AKT1 or PTEN genes, which are found in approximately half of patients with advanced breast cancer.

Read more:
How AI could transform breast screening results
Breast cancer cases and deaths set to surge – study

Prof Turner says hundreds of patients could see the benefit in the immediate future, with thousands more people identified over time.

“We need new drugs that will help our existing therapies work for longer, and that’s where this new drug, capivasertib comes in,” says Prof Turner.

“It doubles how long hormone therapy treatment works for, giving patients precious extra time with their families.”

He called for urgent genetic testing of patients with advanced breast cancers to see if they could benefit.

Continue Reading

Politics

Grayscale and Osprey end 2-year legal fight over Bitcoin ETF promotion

Published

on

By

Grayscale and Osprey end 2-year legal fight over Bitcoin ETF promotion

Grayscale and Osprey end 2-year legal fight over Bitcoin ETF promotion

Asset managers Osprey Funds and Grayscale Investments agreed to settle a lawsuit over alleged violations of Connecticut law in the advertising and promotion of Grayscale’s Bitcoin exchange-traded fund (ETF). 

According to an April 9 court filing, the parties agreed to settle the two-year-old case and are finalizing documentation and settlement terms. The filing noted that once those steps are completed, Osprey will withdraw its appeal.

“Soon after this appeal was filed, the parties reached a settlement of this case,” the motion stated. “It is expected that all these tasks can be done within 45 days, and it is uncertain whether a shorter extension would suffice.”

Details of the settlement have not been made public. 

Grayscale and Osprey reach settlement

The legal battle between the two firms started on Jan. 30, 2023, when Osprey filed a suit in the Connecticut Superior Court. Osprey claimed it was Grayscale’s only competitor in the over-the-counter Bitcoin (BTC) trust market and that Grayscale had maintained its market share through deceit. 

Osprey claimed Grayscale promoted its Grayscale Bitcoin Trust (GBTC) as a means to access a spot Bitcoin ETF through a conversion. Osprey argued that the conversion was presented as a certainty, despite regulatory uncertainty at the time.

Grayscale’s application to convert GBTC into a spot ETF was approved by the US Securities and Exchange Commission in January 2024.

An August 2023 ruling compelled the SEC to reconsider its rejection of Grayscale’s application to convert the fund into an ETF. 

The SEC’s approval allowed GBTC to transition into a spot ETF and begin trading on the NYSE Arca exchange.

Related: Crypto ETPs shed $240M last week amid US trade tariffs — CoinShares

Lawsuit settlement follows Osprey appeal 

On Feb. 7, Judge Mark Gould sided with Grayscale, ruling that Osprey’s claims against the asset manager were exempted from the Connecticut Unfair Trade Practices Act. 

Osprey responded by filing a motion for reargument on Feb. 10. The fund claimed that Gould’s ruling came “before the close of discovery,” which is the formal evidence-gathering phase of a lawsuit.

The fund claimed that the ruling overlooked the differences between how the Federal Trade Commission and Connecticut courts treat deceptive advertising. 

The settlement ended one of the more prominent legal clashes among crypto asset managers competing for early ETF dominance. Grayscale’s GBTC remains one of the largest Bitcoin investment vehicles in the United States.

Magazine: Illegal arcade disguised as … a fake Bitcoin mine? Soldier scams in China: Asia Express

Continue Reading

Trending